UNIGE document Scientific Article
previous document  unige:7096  next document
add to browser collection
Title

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients

Authors
Battegay, M.
Vernazza, P. L.
Flepp, Markus
Erb, P.
Malinverni, R.
show hidden authors show all authors [1 - 11]
Published in HIV Medicine. 2001, vol. 2, no. 1, p. 35-42
Abstract OBJECTIVE: To assess the short-term and long-term effect of a combination of saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed protease inhibitor-naive patients. DESIGN: Prospective open-label multicentre study. PATIENTS AND METHODS: A total of 64 protease inhibitor-naive and stavudine-naive HIV-infected patients with a CD4 count of < 250 cells/microL and > 10 000 HIV-1 RNA copies/mL received saquinavir hard-gelatin capsules, ritonavir and stavudine. Full (drop in viraemia of > 2 log10 and/or < 500 copies/mL) and partial responders (drop to between 500 and 5000 viraemia copies/mL) at week 9 (end of phase I) entered the second phase (additional 12-month period). RESULTS: Fifty-six patients completed phase I, 45 (70%) full responders and nine (14%) partial responders by intent-to-treat analysis. Thirty-nine patients completed phase II, 33 (52%) full responders and two (3%) partial responders. Six patients had < 50 HIV-1 RNA copies/mL at week 9, and 20 (31%) patients at month 12 of phase II. Mean CD4 cell counts increased significantly in the 56 patients from 89 to 184 cells/microL after 9 weeks and from 100 to 292 cells/microL in the 39 patients treated for another 12 months. Higher baseline viraemia and lower baseline CD4 cell counts were not associated with an unfavourable virological response at week 9 and month 12 of phase II. HIV DNA in peripheral blood monocytes decreased substantially (- 1.5 log10) but was detectable in all except one patient at the end of phase II. CONCLUSION: In protease- and stavudine-naive HIV-infected patients with moderate to severe immunosuppression, saquinavir in combination with ritonavir and stavudine caused a substantial long-term decrease in plasma viral load in approximately half the participants and a substantial increase in CD4 cell counts.
Keywords AdolescentAdultAgedCohort StudiesDrug Administration ScheduleDrug Therapy, CombinationFemaleHIV Infections/ drug therapyHIV Protease Inhibitors/administration & dosage/ therapeutic useHumansImmunocompromised HostMaleMiddle AgedProspective StudiesReverse Transcriptase Inhibitors/administration & dosage/ therapeutic useRitonavir/administration & dosage/ therapeutic useSaquinavir/administration & dosage/ therapeutic useStavudine/administration & dosage/ therapeutic useSwitzerlandTreatment OutcomeViral Load
Identifiers
PMID: 11737374
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Structures
Citation
(ISO format)
BATTEGAY, M. et al. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. In: HIV Medicine, 2001, vol. 2, n° 1, p. 35-42. doi: 10.1046/j.1468-1293.2001.00047.x https://archive-ouverte.unige.ch/unige:7096

373 hits

0 download

Update

Deposited on : 2010-06-21

Export document
Format :
Citation style :